Piramal Enterprises Limited

NSE PEL.NS

Piramal Enterprises Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 166.61 M

Piramal Enterprises Limited Net Cash Used Provided By Financing Activities is USD 166.61 M for the year ending March 31, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Piramal Enterprises Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -920.32 M, a -425.30% change year over year.
  • Piramal Enterprises Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 282.92 M, a 116.38% change year over year.
  • Piramal Enterprises Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -1.73 B, a -211.65% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
NSE: PEL.NS

Piramal Enterprises Limited

CEO Mr. Yesh Nadkarni
IPO Date Jan. 2, 1996
Location India
Headquarters Piramal Ananta
Employees 13,706
Sector Healthcare
Industries
Description

Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

Similar companies

APOLLOHOSP.NS

Apollo Hospitals Enterprise Limited

USD 77.32

-1.46%

MUTHOOTFIN.NS

Muthoot Finance Limited

USD 25.56

0.24%

CHOLAFIN.NS

Cholamandalam Investment and Finance Company Limited

USD 15.72

-0.37%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.11

2.83%

AUROPHARMA.NS

Aurobindo Pharma Limited

USD 13.57

-0.25%

StockViz Staff

February 8, 2025

Any question? Send us an email